Cargando…

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E(2) (PGE2) that has been p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Dan, Yin, Liyuan, Huang, Lin, Qin, Changlong, Zhou, Yuwen, Wu, Qiang, Li, Yan, Zhou, Qinghua, Li, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952860/
https://www.ncbi.nlm.nih.gov/pubmed/33718229
http://dx.doi.org/10.3389/fonc.2021.637504
_version_ 1783663823957262336
author Pu, Dan
Yin, Liyuan
Huang, Lin
Qin, Changlong
Zhou, Yuwen
Wu, Qiang
Li, Yan
Zhou, Qinghua
Li, Lu
author_facet Pu, Dan
Yin, Liyuan
Huang, Lin
Qin, Changlong
Zhou, Yuwen
Wu, Qiang
Li, Yan
Zhou, Qinghua
Li, Lu
author_sort Pu, Dan
collection PubMed
description The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E(2) (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.
format Online
Article
Text
id pubmed-7952860
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79528602021-03-13 Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer Pu, Dan Yin, Liyuan Huang, Lin Qin, Changlong Zhou, Yuwen Wu, Qiang Li, Yan Zhou, Qinghua Li, Lu Front Oncol Oncology The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E(2) (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment. Frontiers Media S.A. 2021-02-26 /pmc/articles/PMC7952860/ /pubmed/33718229 http://dx.doi.org/10.3389/fonc.2021.637504 Text en Copyright © 2021 Pu, Yin, Huang, Qin, Zhou, Wu, Li, Zhou and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pu, Dan
Yin, Liyuan
Huang, Lin
Qin, Changlong
Zhou, Yuwen
Wu, Qiang
Li, Yan
Zhou, Qinghua
Li, Lu
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
title Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
title_full Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
title_fullStr Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
title_full_unstemmed Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
title_short Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
title_sort cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952860/
https://www.ncbi.nlm.nih.gov/pubmed/33718229
http://dx.doi.org/10.3389/fonc.2021.637504
work_keys_str_mv AT pudan cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT yinliyuan cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT huanglin cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT qinchanglong cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT zhouyuwen cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT wuqiang cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT liyan cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT zhouqinghua cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer
AT lilu cyclooxygenase2inhibitorapotentialcombinationstrategywithimmunotherapyincancer